Angiotensin Receptor-Neprilysin Inhibitor Therapy and Cardiac Remodeling in Heart Failure: Consensus Statement from India. Other Scholarly Work

Chopra, HK, Wander, GS, Nair, Tiny et al. (2023). Angiotensin Receptor-Neprilysin Inhibitor Therapy and Cardiac Remodeling in Heart Failure: Consensus Statement from India. . The Journal of the Association of Physicians of India, 71(4), 11-12.

cited authors

  • Chopra, HK; Wander, GS; Nair, Tiny; Ponde, CK; Nanda, Navin C; Narula, Jagat; Ray, Saumitra; Venugopal, K; Iyengar, SS; Kasliwal, RR; Chandra, Praveen; Prakash, Sunil; Bansal, Sandeep; Rana, DS; Kerkar, Prafulla; Dasbiswas, Arup; Sawhney, Jps; Shanmungasundram, S; Kumar, Viveka; Vijayalakshmi, IB; Pancholia, AK; Sharma, Vinod; Kapoor, Aditya; Swami, Onkar C; Isser, HS; Rastogi, Vishal; Arora, YK; Omar, Ashok K; Sathe, Sunil; Rajput, Rajeeve; Prabhakar, D; Paul, G Justin; Jagia, Priya; Malhotra, Poonam; Suryaprakash, G; Mittal, Vinod; Jagia, Manish; Jabir, A; Mishra, SS; Routray, SN; Sinha, Ajay Kumar; Bhargava, Mohan; Mahmood, Kiran; Lal, Shreya; Dabhade, Dhammdeep; Bhatia, Mona; Kalra, Pramila; Katyal, VK; Tandon, Rohit; Grover, Rahul; Chhabra, Abhinav; Shastry, NR

authors

abstract

  • Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), β-blockers, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR).

publication date

  • April 1, 2023

published in

keywords

  • Angiotensin Receptor Antagonists
  • Antihypertensive Agents
  • Heart Failure
  • Humans
  • Neprilysin
  • Stroke Volume
  • Tetrazoles
  • Treatment Outcome
  • Ventricular Remodeling

Medium

  • Print

start page

  • 11

end page

  • 12

volume

  • 71

issue

  • 4